Conference report: Deucravacitinib improves signs, symptoms of psoriatic arthritis

Ongoing study (n=203) of this oral tyrosine kinase 2 inhibitor met primary endpoint of ≥20% improvement in signs & symptoms of psoriatic arthritis [at week 16, 52.9% & 62.7% on 6 & 12mg dose experienced improvements in disease vs 31.8% placebo; p=0.0134 & p=0.0004, respectively).

Source:

Biospace Inc.